Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 36Neoplasms 8Lung Neoplasms 7Neoplasm Metastasis 4Neoplasms by Site 3Lymphoma, Large-Cell, Anaplastic 3Hematologic Neoplasms 3Breast Neoplasms 3Brain Neoplasms 3Thyroid Neoplasms 2Sarcoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasms by Histologic Type 2Lymphoproliferative Disorders 2Gastrointestinal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Urinary Bladder Neoplasms 1Thyroid Cancer, Papillary 1Thoracic Neoplasms 1Solid Tumors 1Sexual Dysfunction, Physiological 1Salivary Gland Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Rare Tumour 1Rare Tumor 1Prostatic Neoplasms 1Neuroendocrine Tumors 1

Interventions

veliparib 1vandetanib 1pralsetinib 1osimertinib 1cemiplimab 1alectinib 1Vascular Endothelial Growth Factor A 1Temozolomide 1Sorafenib 1Paclitaxel 1Liquid Biopsy 1GSK3352589 1Docetaxel 1Crizotinib 1Carboplatin 1Capecitabine 1Antibodies, Bispecific 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Endocrine Neoplasia Type 2a × alectinib × Clear all
NCT03194893 2026-05-20

A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

Hoffmann-La Roche

Phase 3 Active not recruiting
200 enrolled
EndocrineThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Multiple Endocrine Neoplasia Type 2a

Data powered by HemOnc (CC BY 4.0) Colophon âš¡